In patient-derived neurons, tau mutations scupper lysosomes and SORLA shunts APP through different types of endosomes.
Using a form of confocal microscopy and automated software, the method allows researchers to rapidly identify functional synapses within brain structures.
The drug slows functional decline in patients with mild disease and should be available to U.S. patients in August.
The ALS Ice Bucket Challenge has yielded more than $100 million—what research projects should get a share of the action?
Amyotrophic lateral sclerosis, already a rare condition affecting one to three people in 100,000, nonetheless garners most of the attention in the field of motor neuron disease...
People who lived in impoverished neighborhoods in their last year of life had greater odds of having died with AD neuropathology.
Islet amyloid protein and Aβ fibrils share similar folds.
Prompted by striking brain pathology in both contact sport athletes and military veterans, scientists are now defining a new disease...
Autopsy data confirm that current tau PET tracers are unsuitable for some primary tauopathies. CryoEM structures help researchers find new ligands for tau and α-synuclein.
At the HAI 2020 conference, the tracers PI-2620 and APN-1607 appeared to bind frontotemporal dementia tau. MK-6240 looked highly sensitive. And JNJ-067 and SNFT-1 are two new kids in town.
CryoEM helps explain how the inhibitory receptors open and close their ion channels.
The findings hint at a liver-brain axis that transmits inflammation from periphery to brain, and could suggest therapeutic targets for preserving brain function.
The tracer distinguished people with progressive supranuclear palsy from controls with a sensitivity of 85 percent, suggesting potential as a diagnostic for 4R tauopathies.
In striatal spiny projection neurons with mutant huntingtin, mitochondria spill immunogenic RNAs into the cytosol. These touch off innate antiviral signaling inside the neurons, which may spell their demise.
A slight drop in hospital admissions after amyloid PET, especially in people with positive scans, fell well short of the prespecified endpoint. Still, IDEAS is broadening into a research platform, and IDEAS 2 will add racial diversity.